The modification is part of the material's identity and must be supported by documentation. A generic peptide purity result doesn't prove that every relevant attachment is correct. Expected mass and appropriate characterization help define what was tested. If a report names only CJC 1295, clarify whether it actually describes the with DAC material.
Representative product imagery. Verify the physical label and lot documentation on receipt.
Growth Signaling
CJC-1295 with DAC
In stock·Ships in 1–2 business days
CJC-1295 with DAC research material supplied with batch-level documentation. Each unit is labeled with a traceable lot code and links to its corresponding analytical report.
Select size1 option
Select pack sizeSave 18% on kits
1 × 5 mg$102.99
In stockSelected size 5 mgSC-CD5-005
Transparent volume pricing10-vial peptide kits save 18%.
Secure checkout US & EU dispatch
Research use only acknowledgment required at checkout
Report not published
Compound context
What researchers study
CJC-1295 with DAC is a modified GHRH analog associated with prolonged exposure in published endocrine research. DAC identity is central to this listing. Laboratories comparing it with another CJC material should check the modification and sequence rather than relying on an abbreviated name. The available research quantity is shown in the product selector.
A published study in healthy adults measured prolonged growth hormone and IGF I responses after CJC-1295 exposure. Those findings describe the investigated compound and protocol. They don't establish a general muscle growth benefit or transfer automatically to a catalog product called CJC-1295 without DAC. Receptor signaling and persistence in circulation are also different properties.
Binding to proteins can alter the free fraction of a compound in a test matrix. A nominal concentration therefore may not describe the fraction available to a receptor at a given time. The protein content of an assay and the measurement interval belong beside the result. Comparisons need consistent conditions before a potency difference can be interpreted.
Scope limitConfirm the DAC modification in the batch documentation and retain the analytical identity record. Research use excludes personal administration or endocrine treatment. Clinical study amounts aren't a preparation guide for this material.
Serenity Compounds is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act.
Common laboratory focus
Published prolonged response research examined hormone concentrations over time in a defined group of adults. An endocrine biomarker is not the same as measured muscle strength or clinical benefit. When using the paper as background, preserve its population and its actual outcomes. A research purchase doesn't establish equivalence to the administered study formulation.
Different persistence properties can change the relationship between sampling time and observed response. A comparison should state whether it tests receptor activity in vitro or exposure in a larger biological system. The same nominal mass doesn't guarantee comparable receptor exposure. Sequence identity and the chosen endpoint determine which comparison is meaningful.
Quality documentation
Know what your laboratory receives.
Batch records are published for transparency and should be independently reviewed by qualified research personnel.
Current certificateCJC-1295 with DAC · Report not publishedSee original reportView report
- Tamper-evident packaging
- Lot and SKU traceability
- Independent analytical review
Continue exploring
